California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2) - Nexcella, Inc
Summary
LOS ANGELES, CA, July 25, 2024 Nexcella, Inc. (Nexcella, Company, We or Us), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and autoimmune disease, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded Nexcella an $8 million CLIN2 grant award to support clinical development of its chimeric antigen receptor T cell (CAR-T) therapy NXC-201 for the treatment of relapsed/refractory AL Amyloidosis.AL amyloidosis is an unmet medical need, and current approved therapies for this rare disease are mostly not well tolerated and have not led to sustained remissions, said Dr. Abla Creasey, PhD, Vice President of Therapeutics Development at CIRM. Gabriel Morris, President of Nexcella, added, We are excited to join Californias thriving CIRM biotechnology innovation ecosystem as we proceed on-plan with NEXICART-2.The NEXICART-2 U.S. study is intended to evaluate the safety and efficacy of NXC-201 in relapsed/refractory AL Amyloidosis patients with adequate cardiac function who have not been exposed to prior BCMA-targeted therapy. The best responder experienced a 28.0 month duration of response (as reported May 10, 2024, with ongoing follow-up).NXC-201 is the only CAR-T therapy currently in development in AL Amyloidosis, mentioned in a .About the California Institute for Regenerative Medicine (CIRM)At CIRM, we never forget that we were created by the people of California to accelerate stem cell treatments to patients with unmet medical needs, and act with a sense of urgency to succeed in that mission. To meet this challenge, our team of highly trained and experienced professionals actively partners with both academia and industry in a hands-on, entrepreneurial environment to fast track the development of todays most promising stem cell technologies.With $5.5 billion in funding and more than 150 active stem cell programs in our portfolio, CIRM is one of the worlds largest institutions dedicated to helping people by bringing the future of cellular medicine closer to reality.About NEXICART-2 NEXICART-2 (NCT06097832) is an open-label, single-arm, multi-site U.S. Immix Biopharma does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law.